Highlighted Publications

Clinical Investigations on Leukemia

Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: Golden anniversary. Nature Reviews Clinical Oncology. 2009; 6(11): 638-647.

Emadi A, Zokaee H, Sausville EA. Asparaginase in the Treatment of Non-ALL Hematologic malignancies. Cancer Chemotherapy and Pharmacology. 2014; 73(5):875-883.

Sammons SL, Pratz KW, Smith BD, Karp JE, Emadi A. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant, and after relapse post-transplant. American Journal of Hematology. 2014; 89(9):936-938.

Oliver N, Short B, Thein M, Duong VH, Tidwell ML, Sausville EA, Baer MR, Kamangar F, Emadi A. Treatment of Catheter-related Deep Vein Thrombosis in Acute Leukemia Patients with Anticoagulation. Leukemia & Lymphoma. 2015; 56(7):2082-2086.

Etemadi A, Kamangar F, Islami F, Poustchi H, Pourshams A, Brennan P, Boffetta P, Malekzadeh R, Dawsey SM, Abnet CC, Emadi A. Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study. BMC Medicine. 2015;13(1):8.

Fathi AT, Wander SA, Faramand R, Emadi A. Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia. Seminars in Hematology. 2015; 52(3):165-171.

Emadi A. Exploiting AML Vulnerability: Glutamine Dependency. Blood. 2015; 126(11):1269-1270.

Emadi A, Bade NA, Stevenson B, Singh Z. Minimally-myelosuppressive asparaginase-containing induction regimen for treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS acute myeloid leukemia. Pharmaceuticals (Basel). 2016; 9(1), 12; doi:10.3390/ph9010012.

Babakoohi S, Lapidus RG, Faramand R, Sausville EA, Emadi A. Comparative analysis of methods for detecting isocitrate dehydrogenase 1 and 2 mutations and their metabolic consequence, 2-hydroxyglutarate, in different neoplasms. Applied Immunohistochemistry & Molecular Morphology. 2017; 25(5):334-337.

Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Mewre I, Philips S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh ZN, Bentzen AM. Asparaginase Erwinia Chrysanthemi Effectively Depletes Plasma Glutamine in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia. Cancer Chemotherapy and Pharmacology. 2018; 81(1):217-222.

El Chaer F, Ali OM, MD, Sausville EA, Law JY, Lee ST, Duong VH, Baer MR, Koka R, Singh ZN, Wong J, Yared JA, Griffiths EA, Emadi A. Treatment of CD19-Positive Mixed Phenotype Acute Leukemias with Blinatumomab. American Journal of Hematology. 2019;94(1):E7-E8.

Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Law JY, Lee ST, Sausville EA, Zimrin AB, Duffy AP, Lawson J, Emadi A. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. Journal of Oncology Pharmacy Practice. 2020;26(1):74-92.

Pratz KW, Rudek MA, Smith BD, Karp J, Gojo I, Dezern A, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Rosner G, Zahurak M, Wright JJ, Emadi A, Levis M; ETCTN-8922 study team. A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation. Biology of Blood and Marrow Transplantation. 2020;26(2):300-306.

Holtzman NG, El Chaer F, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A. Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. British Journal of Haematology. 2020;188(6):881-887.

Estey E, Karp JE, Emadi A, Othus M, Gale RP. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020;34(3):671-681.

Patzke CL, Duffy AP, Duong VH, El Chaer F, Trovato JA, Baer MR, Bentzen SM, Emadi A. Comparison of high-dose cytarabine, mitoxantrone, pegaspargase (HAM-pegA) to high-dose cytarabine, mitoxantrone, cladribine, and filgrastim (CLAG-M) as first-line salvage cytotoxic chemotherapy for relapsed/refractory acute myeloid leukemia. Journal of Clinical Medicine. 2020;9(2):536(1-8).

Niyongere S, Sanchez-Petitto G, Masur J, Baer MR, Duong VH, Emadi A. Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Pharmaceuticals (Basel). 2020; 13(6):124;doi: 10.3390/ph13060124.

Basic/Translational Investigations on Leukemia

Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Inhibition of glutaminase selectively suppresses the growth of primary AML cells with IDH mutations. Experimental Hematology. 2014; 42(4): 247-251.

Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA. Presence of isocitrate dehydrogenase (IDH) mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia (AML). American Journal of Hematology. 2015; 90(5):E77-79.

Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia. Leukemia Research. 2015; 39(7):719-729.

Emadi A, Kapadia B, Bollino D, Bhandary B, Baer MR, Niyongere S, Strovel ET, Kaizer H, Chang E, Choi EY, Ma X, Tighe KM, Carter-Cooper B, Moses BS, Civin CI, Mahurkar A, Shetty AC, Gartenhaus RB, Kamangar F, Lapidus RG. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia. Leukemia. 2021 Jul; 35(7); 1907-1924.

Kapadia B, Shetty AC, Bollino D, Bhandary B, Lapidus RG, Mahmood K, Mahurkar A, Gartenhaus RB, Eckert RL, Emadi A. Translatome changes in acute myeloid leukemia cells post exposure to pegcrisantaspase and venetoclax. Exp Hematol. 2022 Apr;108:55-63.

Bollino D, Claiborne JP, Hameed K, Ma X, Tighe KM, Carter-Cooper B, Lapidus RG, Strovel ET, Emadi A. Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine. Front Oncol. 2022;12:1035537doi: 10.3389/fonc.2022.1035537. eCollection 2022. 

Naphthoquinone Chemotherapeutics

Emadi A, Harwood JS, Kohanim S, Stagliano KW. Regiocontrolled synthesis of the trimeric quinone framework of conocurvone. Organic Letters. 2002; 4(4): 521-524.

Stagliano KW, Emadi A*, Lu Z, Malinakova HC, Twenter B, Yu M, Holland LE, Rom AM, Harwood JS, Amin R, Johnson AA, Pommier Y. Regiocontrolled synthesis and HIV inhibitory activity of unsymmetrical binaphthoquinone and trimeric naphthoquinone derivatives of conocurvone. Bioorganic and Medicinal Chemistry. 2006; 14(16): 5651-5665.

Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M. A chemical genetic screen for modulators of asymmetrical 2,2´-dimeric naphthoquinone cytotoxicity in yeast. PLoS One. 2010; 5(5):e10846.

Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M. Dimeric naphthoquinones represent a novel class of compounds with prostate cancer cytotoxicity. British Journal of Urology International. 2011; 108(3): 447-454.

Emadi A, Le A, Harwood CA, Stagliano KW, Kamangar F, Ross AE, Cooper CR, Dang CV, Karp JE, Vuica-Ross M. Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells. Bioorganic and Medicinal Chemistry. 2011; 19(23): 7057-7062.

Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Mukhi Pidugu LS, Jaiswal AK, Toth EA, Rassool FV, Etemadi A, Sausville EA, Baer MR, Emadi A. Hydroxylated dimeric naphthoquinones increase generation of reactive oxygen species, induce apoptosis of AML cells and are not substrates of the multidrug resistance proteins. Pharmaceuticals (Basel). 2016; 9(1), 4; doi:10.3390/ph9010004

Mukhi Pidugu LS, Mbimba JCE, Ahmad M, Pozharski E, Sausville EA, Emadi A, Toth EA. A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone. BMC Structural Biology. 2016; 16(1):1-10.

Carter-Cooper BA, Fletcher S, Ferraris D, Choi EY, Kronfli D, Dash S, Truong P, Sausville EA, Lapidus RG, Emadi A. Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells. Bioorganic & Medicinal Chemistry Letters. 2017; 27(1):6-10.

Lee MH, Lapidus RG, Ferraris D, Emadi A. Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics. Molecules. 2019;24(17), pii: E3121.

Ferraris D, Lapidus R, Truong P, Bollino D, Carter-Cooper B, LeeM, Chang E, LaRossa-Garcia M, Dash S, Gartenhaus R, Choi EY, Kipe O, Lam V, Mason K, Palmer R, Williams E, Ambulos N, Kamangar F, Zhang Y, Kapadia B, Jing Y, Emadi A. Pre-Clinical Activity of Amino-Alcohol Dimeric Naphthoquinones as Potential Therapeutics for Acute Myeloid Leukemia. Anticancer Agents Med Chem. 2022; 22(2): 239-253.